Overview Hematopoietic cell transplant (HCT) recipients are at a heightened risk of a wide range of new infections or the reactivation of latent or remote infections given the extent of immunosuppression and immune dysregulation caused by chemotherapy, immunosuppressive medications for…
Background: Natural Killer Cell Biology In 1973, Ivan Roitt's laboratory identified a new class of lymphocytes dubbed “null” killer cells, since they were neither T-cells nor B cells. The following year, these “null” lymphocytes were found to have spontaneous ability…
Introduction to Germ-Cell Tumors Germ-cell tumors (GCT) are the most common malignancy in young men ages 15 to 35 years. These tumors have great response rates to cisplatin-based chemotherapy, with cure rates for metastatic disease as high as 70% to…
Introduction There is an expanding role for hematopoietic cell transplantation (HCT) in rare hematologic malignancies. The rarity of these diseases limit well-designed prospective trials. In this chapter, we review the available data on the role of allogeneic and autologous HCT…
Introduction Clinical trials of CD19 chimeric antigen receptor (CAR) T-cells have demonstrated promising survival outcomes and response rates in relapsed and/or refractory (r/r) non-Hodgkin lymphoma (NHL), providing a potentially curative treatment option for these heterogeneous, aggressive malignancies. There are currently…
Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy composed of two distinct disease entities: the more commonly diagnosed classical HL and the rare nodular lymphocyte predominant HL. The disease has a bimodal distribution with an increased incidence in young…
Introduction Non-Hodgkin lymphoma (NHL) is a lymphoid malignancy that represents 4.3% of all new cancer diagnosis in the United States and is estimated to be responsible for over 19,000 deaths in 2020. While newer immunotherapies have emerged that have improved…
Introduction Light chain (AL) amyloidosis is a plasma cell disorder characterized by the deposition of monoclonal immunoglobulin light chains in a variety of tissues leading to organ dysfunction. The treatment of this disorder focuses on eliminating the plasma cells producing…
Introduction Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells within the bone marrow microenvironment causing organ dysfunction that may include anemia, lytic bone lesions, hypercalcemia, and renal dysfunction. In 2021, myeloma was expected…
Introduction The goal of treatment for multiple myeloma, an incurable hematologic malignancy, is to achieve the deepest possible response with the longest duration of remission upfront to achieve a durable disease-free state. The pivotal multicenter trial IFM 90 established the…